









Markets
/
Stocks
/
nasdaq-cgen
/

Compugen Ltd

CGEN

1.330USD

-0.010-0.75%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

124.40MMarket Cap

LossP/E TTM



Compugen Ltd

1.330

-0.010-0.75%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

133 / 506

Overall Ranking

241 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Strong Buy

Current Rating

7.000

Target Price

+422.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 271.52% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 27.86M.

Overvalued

The company’s latest PE is -6.32, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 18.05M shares, decreasing 11.38% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 1.33M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.25, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.26M, representing a year-over-year decrease of 81.24%, while its net profit experienced a year-over-year decrease of 245.83%.

Score

Industry at a Glance

Previous score

6.25

Change



Financials

8.68

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.54

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.04

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -6.37, which is 26.15% below the recent high of -8.04 and -64.93% above the recent low of -10.51.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 133/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 9.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Compugen Ltd is 4.00, with a high of 13.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

9.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Strong Buy

Current Rating

7.000

Target Price

+422.39%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Compugen Ltd

CGEN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.28, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.45 and the support level at 1.27, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.28

Change

-0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.010

Sell

RSI(14)

36.181

Neutral

STOCH(KDJ)(9,3,3)

14.772

Sell

ATR(14)

0.054

High Vlolatility

CCI(14)

-116.183

Sell

Williams %R

93.333

Oversold

TRIX(12,20)

-0.309

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.358

Sell

MA10

1.381

Sell

MA20

1.405

Sell

MA50

1.463

Sell

MA100

1.510

Sell

MA200

1.636

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 19.34%, representing a quarter-over-quarter decrease of 4.89%. The largest institutional shareholder is James Simons, holding a total of 1.33M shares, representing 1.42% of shares outstanding, with 0.53% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

SilverArc Capital Management, LLC

2.90M

+78.25%

Bristol Myers Squibb

1.84M

-61.32%

Renaissance Technologies LLC

Star Investors

1.40M

+9.24%

ARK Investment Management LLC

Star Investors

889.67K

Macquarie Investment Management

1.02M

Taylor Frigon Capital Management LLC

1.05M

-4.00%

Rock Springs Capital Management LP

989.99K

Northern Trust Global Investments Limited

881.24K

-6.43%

Morgan Stanley Smith Barney LLC

802.50K

+3.07%

Morgan Stanley & Co. LLC

583.91K

+1328.64%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.21, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.